Custom Software

Computer Vision in Medical Imaging: Engineering AI for Radiology, Pathology, and Specialty Imaging Workflows

Computer vision in medical imaging is the application of convolutional neural networks, vision transformers, and multi-modal models to medical image data — radiology DICOM studies, digital pathology whole-slide images, ophthalmology fundus photographs, dermatology images, cardiology echocardiograms, and surgical video. Production-grade medical imaging AI requires DICOM-native data pipelines, PACS integration, model architectures matched to the modality, validation against radiologist or pathologist gold standards, FDA SaMD pathway awareness for regulated-device-track deployments, and HIPAA-compliant deployment with audit logging.

Medical imaging AI is the most clinically mature AI category in healthcare. Hundreds of FDA-cleared imaging AI devices are in production use across US hospitals in 2026, with the strongest concentration in radiology and a rapidly growing footprint in digital pathology. The engineering discipline is older than generative AI by a decade and operates on different principles — different data formats (DICOM, not EHR text), different model architectures (CNNs and vision transformers, not LLMs), different validation methodology (radiologist gold standards, not BLEU scores), and a sharper FDA regulatory line.

Taction Software® has built and integrated medical imaging AI for healthtech companies, hospital innovation teams, and enterprise health systems — across radiology, pathology, ophthalmology, dermatology, and cardiology workflows. This page is the engineering and deployment framework.

Calculate My Project Cost Connect With Experts

Tell Us Your Requirements

Our experts are ready to understand your business goals.

Trusted Partners

Trusted by Industry Leaders Worldwide

Recognition

Awards & Recognitions

What Is Computer Vision in Medical Imaging?

Computer vision in medical imaging is software that analyzes medical images to detect, classify, segment, measure, or quantify clinical findings. The output varies by use case — a binary classification (“nodule present / not present”), a probability (“likelihood of malignancy”), a segmentation mask (“here is the tumor boundary”), a measurement (“this lesion is 14mm”), or a structured report draft.

Production-grade medical imaging AI has six properties.

It runs on real DICOM data. Production medical imaging is DICOM (Digital Imaging and Communications in Medicine) — not JPEG, not PNG, not stripped pixel arrays. Pixel data, metadata (patient, study, series, instance), and clinical context all travel together. Models trained on stripped or converted images often fail in production because the metadata and acquisition parameters they didn’t see in training are present in real studies and shift the input distribution.

It integrates with the PACS, not alongside it. Production medical imaging workflows happen inside the Picture Archiving and Communication System — the radiologist’s reading workstation, the pathologist’s whole-slide-image viewer, the cardiologist’s echo system. AI that requires the clinician to switch out of the PACS gets ignored. Integration patterns vary across PACS vendors but are well-established.

Validation against clinician gold standards. A medical imaging model is validated against radiologist or pathologist consensus on a held-out test set — not against a public benchmark. Sensitivity, specificity, AUROC, and (where applicable) dice coefficient or intersection-over-union for segmentation tasks. Subgroup performance across imaging vendor, scanner model, body region, and patient demographics.

FDA SaMD pathway awareness from project inception. Medical imaging AI sits closer to FDA’s Software as a Medical Device (SaMD) framework than any other healthcare AI category. The 510(k), De Novo, and breakthrough-device pathways are part of the project conversation from week one for clinical-decision-supporting use cases — not bolted on at the end.

Specialty workflow fit. Radiology, pathology, ophthalmology, dermatology, and cardiology each have specialty-specific workflow patterns. The same underlying model architecture serves different workflows differently. Specialty literacy on the engineering team is what separates an AI feature that gets adopted from one that gets uninstalled.

HIPAA compliance with audit logging. PHI travels with DICOM metadata. Audit logging of every model inference, every output rendered, every structured-report write-back has to meet §164.312(b). Encryption, RBAC, BAA paper trail with model and cloud providers — same requirements as any healthcare AI system, with imaging-specific implementation.

These six properties are the floor. Specific use cases add capabilities — multi-modal integration combining imaging with EHR data, longitudinal change detection across studies, FDA pre-submission documentation for novel device classifications.

Why Medical Imaging AI Is Different from Generative AI in Healthcare

Three structural differences matter for engineering decisions.

Different data format and infrastructure. Generative AI runs on text and structured data accessible via FHIR. Medical imaging AI runs on DICOM, accessible via DICOMweb (QIDO-RS, WADO-RS, STOW-RS), retrieved from PACS, archived in VNAs (Vendor Neutral Archives), and rendered in specialty viewers. The integration surface is entirely different from EHR-text AI; engineering depth on DICOM and PACS is non-substitutable.

Different model architectures and training. Generative AI engineering centers on LLM selection, prompt engineering, and RAG. Medical imaging AI engineering centers on CNN architectures (ResNet variants, U-Net, Mask R-CNN), vision transformers (ViT, Swin), specialty-specific architectures (3D U-Net for volumetric data, multiple-instance learning for whole-slide pathology), training infrastructure (GPU clusters for training, not just inference), and data augmentation strategies that handle the variability of clinical imaging. The skill set is partially overlapping but not interchangeable.

Different regulatory surface. Generative AI in healthcare typically positions as a drafting copilot with the clinician retaining decision authority — which keeps most generative use cases below the FDA SaMD threshold. Medical imaging AI that detects, classifies, or quantifies findings used in clinical decisions is much closer to SaMD by default. Sensitivity-specificity trade-offs that affect clinical decisions, autonomous decision-making AI, and AI that drives a billable interpretation all sit firmly inside FDA’s regulatory scope. The pathway is not optional for these use cases.

This is why medical imaging engagements at Taction look different from generative engagements — different team composition (radiologists or pathologists on the eval side, ML engineers with imaging-specific experience on the build side, regulatory consultants for FDA pathway work), different deliverable cadence (longer training runs, more validation work), and different operational profile (PACS integration, not EHR integration as the primary surface).

High-Value Use Cases by Specialty

Five specialty domains where medical imaging AI is most mature in 2026.

Radiology

The largest installed base of clinical AI in healthcare. Hundreds of FDA-cleared products across modalities — CT, MRI, X-ray, mammography, ultrasound, nuclear medicine.

High-value use cases. Stroke detection on CT and CTA (large-vessel occlusion identification), pulmonary embolism detection on CTA, intracranial hemorrhage detection on CT head, lung nodule detection on chest CT, breast cancer screening on mammography, fracture detection on X-ray, abdominal aortic aneurysm detection, cardiac function quantification on echocardiogram, and dozens of others. Triage AI (flagging suspected emergent findings to the top of the worklist) is one of the highest-adoption categories.

Engineering pattern. DICOM-native pipeline ingesting from PACS via DICOMweb or DIMSE. Volumetric model architectures (3D U-Net, 3D ResNet) for cross-sectional imaging. Multi-window models for CT. Multi-sequence models for MRI. Output as DICOM-SR (Structured Report), DICOM Secondary Capture, or PACS-integrated worklist priority change.

Where ROI lands. Worklist triage that prioritizes emergent findings reduces time-to-diagnosis on stroke, PE, and ICH — clinical outcomes that compound directly. Detection AI as a second-reader pattern improves sensitivity in screening contexts. Quantification AI replaces manual measurement work.

Digital Pathology

Whole-slide image analysis is one of the fastest-growing imaging AI categories in 2026, accelerating as more pathology departments digitize.

High-value use cases. Cancer detection (prostate, breast, colorectal, gastric, lung), grading (Gleason score, breast cancer grading, lymphoma classification), biomarker quantification (Ki-67, HER2, PD-L1), and rare-finding detection. Tumor-bed assessment, lymph-node metastasis detection, and microsatellite-instability prediction are emerging high-value categories.

Engineering pattern. Multiple-instance learning (MIL) architectures handle the gigapixel scale of whole-slide images by processing tile-level features and aggregating to slide-level predictions. Self-supervised pretraining on unlabeled slides has become a dominant paradigm. Integration with the digital pathology viewer (Aperio, Leica, Philips, Hamamatsu) and the laboratory information system (LIS) is the operational integration target.

Where ROI lands. Pathologist time is the binding constraint in many laboratory operations. AI-assisted grading and biomarker quantification reduce per-case time meaningfully. Decision-support AI for difficult cases improves diagnostic consistency.

Ophthalmology

Fundus photography, OCT (optical coherence tomography), and visual-field testing produce the most data-rich imaging in medicine outside radiology. Diabetic retinopathy screening, glaucoma detection, and AMD (age-related macular degeneration) staging are mature application categories.

Engineering pattern. 2D CNN architectures for fundus photography, volumetric architectures for OCT. Tight integration with retinal-camera workflows is standard — many production deployments are at the point of image acquisition rather than centralized analysis.

Where ROI lands. Diabetic retinopathy screening at primary-care points-of-care expands access without requiring ophthalmology referral for normal screens. Autonomous AI in this category is the most mature in any clinical specialty — with FDA-cleared autonomous detection devices in production use.

Dermatology

Image-based skin lesion classification, mole tracking, and rash differential diagnosis. The clinical AI category most dependent on image quality variability and most affected by demographic skin-tone variation in training data.

Engineering pattern. 2D CNN and vision transformer architectures. Strong attention to subgroup performance across skin tones — a category where training-data representation is historically uneven and where deployment without fairness validation is a clinical-safety failure. Integration with mobile capture (in primary care, telehealth, and patient-facing) is more common than PACS integration in this specialty.

Where ROI lands. Triage AI in primary care identifies high-risk lesions for dermatology referral. Direct-to-patient skin-check applications are a healthtech category with both clinical and direct-consumer business models.

Cardiology Imaging

Echocardiogram analysis, cardiac MRI quantification, coronary CT angiography assessment, and invasive imaging (IVUS, OCT) interpretation.

Engineering pattern. 3D and time-series architectures for echocardiograms (which are 3D + time). Quantification models replace manual measurement work that was historically a major time sink. Integration with cardiology-specific imaging systems and with the cardiac information system.

Where ROI lands. Echo quantification AI reduces sonographer and cardiologist time per study. Coronary CT analysis AI supports a workflow that is rapidly replacing invasive coronary angiography for many indications. Detection AI for valvular disease identifies patients who would benefit from cardiology referral but were missed in upstream workflows.

DICOM and PACS Integration

The medical imaging integration surface is structurally different from the EHR integration surface and requires different engineering depth.

DICOMweb integration patterns. Production medical imaging AI in 2026 integrates via DICOMweb services — QIDO-RS for query, WADO-RS for retrieve, STOW-RS for store. DICOMweb is RESTful, JSON-friendly, and the modern integration target. Legacy DIMSE-based integration is still required for some PACS environments and for some hospital infrastructures that haven’t deployed DICOMweb.

PACS workflow integration. Production AI surfaces inside the radiologist’s reading workstation, not in a separate viewer. Integration patterns include worklist priority change (the AI flags emergent findings to move them to the top of the worklist), structured report generation (the AI’s output written as DICOM-SR for the radiologist to incorporate), and AI-overlaid reading (the AI’s annotations visible alongside the underlying images in the reading viewer). Different PACS vendors support different integration patterns; vendor-specific implementation is part of the engagement scope.

VNA and enterprise imaging considerations. Modern hospitals increasingly route imaging through Vendor Neutral Archives that aggregate across radiology, cardiology, pathology, ophthalmology, dermatology, and surgical-video sources. AI integration at the VNA layer is more flexible than per-modality integration but introduces additional governance considerations.

EHR integration where the imaging AI feeds clinical workflow. Some imaging AI use cases require integration both with PACS (for the imaging data) and with the EHR (for clinical context — patient history, comorbidities, prior imaging) and for the clinical-decision-supporting output. Cross-system integration adds complexity but is the right pattern for use cases where the imaging finding is part of a broader clinical decision.

The integration architecture decision is part of the project scope from inception. Our healthcare data integration practice covers DICOM, HL7 v2 (the underlying transport for many imaging-to-EHR communications), and FHIR R4 patterns including FHIR’s ImagingStudy resource for cross-system imaging metadata exchange.

Section 05

FDA SaMD Pathway for Medical Imaging AI

Medical imaging AI is the category most affected by FDA’s SaMD framework. Understanding the regulatory pathway is part of project scoping, not a post-build consideration.

Three primary pathways. 510(k) clearance for devices that demonstrate substantial equivalence to a legally marketed predicate device — the most common pathway for incremental medical imaging AI. De Novo classification for novel device classifications without a predicate. Pre-market approval (PMA) for the highest-risk classifications.

Risk classification. SaMD risk is determined by the significance of information provided to a healthcare decision (inform, drive, treat/diagnose) crossed with the state of the healthcare situation (non-serious, serious, critical). Higher categories require more rigorous validation, more extensive documentation, and more substantial regulatory engagement.

Validation requirements. FDA expects validation on the intended-use population, on the intended hardware (or representative samples), against a defined gold standard, with subgroup analysis across demographics and acquisition parameters. The validation methodology is part of pre-submission planning; building first and validating later is the most common path to a submission failure.

Post-market surveillance and predetermined change control. Modern FDA guidance increasingly accommodates AI’s continuous-improvement nature through predetermined change control plans (PCCPs) — which let manufacturers update models within bounds defined in the original submission. Engaging with this framework requires regulatory expertise the engineering team alone usually does not possess.

Where Taction’s role lands. Taction is FDA SaMD-aware — we know when an AI feature crosses the SaMD threshold, how to scope the validation methodology to support a future submission, and how to structure the engineering work to align with quality system requirements. For regulatory submission work itself, we partner with regulatory consultants and the customer’s regulatory affairs team. The engineering deliverables (validation reports, eval methodology documentation, risk analysis artifacts) are scoped to support the regulatory pathway from week one.

Production reality

Production Architecture: Six Required Capabilities

Every Taction medical imaging AI deployment includes these six capabilities.

1. DICOM-native pipeline. Inference and training pipelines that process DICOM directly — preserving metadata, handling multi-frame and volumetric data, accommodating modality-specific acquisition parameters. Conversion to JPEG/PNG for inference is a red flag; production pipelines run on DICOM.

2. Model architecture matched to modality. 2D CNN for chest X-ray and dermatology. Volumetric (3D U-Net, 3D ResNet) for CT and MRI. Multiple-instance learning for whole-slide pathology. Time-series architectures for echocardiogram. Vision transformers where they outperform CNNs on the specific use case. Architecture selection is justified, not default.

3. Validation harness with clinician gold standard. A held-out test set labeled by the appropriate clinical specialist (radiologist, pathologist, ophthalmologist, dermatologist, cardiologist) — typically with multi-reader consensus on hard cases. Sensitivity, specificity, AUROC, dice coefficient or IoU for segmentation, subgroup performance, and (for FDA-track devices) reader-study designs that produce regulatory-grade evidence.

4. PACS or imaging system integration. DICOMweb or DIMSE for data ingestion. PACS-vendor-specific patterns for output integration (worklist priority, DICOM-SR, AI-overlay, third-party display protocol). Specialty system integration for non-radiology modalities (digital pathology viewer, retinal camera, echocardiography system).

5. HIPAA-compliant audit logging. Every PHI access through the imaging pipeline, every model inference, every output rendered, every structured-report write-back. §164.312(b)-compliant, retained per §164.530(j), encrypted, append-only.

6. Monitoring and post-market surveillance. Drift detection on input distributions (new scanner model, new acquisition protocol, new patient population). Performance drift against accumulating clinician-labeled outcomes. Subgroup-fairness drift. For FDA-cleared devices, structured post-market surveillance aligned with the predetermined change control plan.

These six layers are the floor. Specific deployments add capabilities — multi-modal architecture combining imaging with EHR data, federated learning across hospital sites, on-prem deployment for hospitals with imaging-data-residency policies. Many of our hospital and health-system imaging AI engagements include on-prem deployment because of the size and sensitivity of imaging data.

Pricing: Three Engagement Tiers

HIPAA + FHIR included. Always.

The Imaging AI Prototype tier is sized for organizations validating whether a medical imaging AI use case will work on their data and against their specialist gold standard. Deliverable: a validation report and a defensible go/no-go on production deployment.

The Production Deployment tier covers HIPAA-compliant production deployment with PACS integration, monitoring, and operational support. Suitable for use cases that don’t cross the FDA SaMD threshold (clinical productivity tools, internal-quality-improvement AI, research applications) or for in-hospital deployments that don’t require commercial regulatory clearance.

The FDA-Track Engagement covers the engineering scope required to support a regulatory submission. Includes validation methodology aligned to FDA expectations, eval studies designed for regulatory-grade evidence, documentation structured for 510(k) or De Novo submission, and predetermined change control plan support. Regulatory submission work itself is partnered with regulatory consultants and the customer’s regulatory affairs team. For the broader healthcare software development engineering practice supporting these engagements, our 13-year healthcare-only track record is the foundation.

For multi-modality engagements, federated learning across hospital sites, on-prem deployment, or specialty-specific work outside the patterns above, pricing is custom. Use the healthcare engineering cost calculator for an estimate.

Build vs. Buy: Medical Imaging AI Decision Framework

The medical imaging AI commercial landscape is the most developed in healthcare AI — hundreds of FDA-cleared products span every major modality and many specialties. The build-vs-buy decision turns on five factors.

Book a Discovery Call

What Makes Taction Different

Three things — verifiable.

Healthcare-only since 2013. 785+ healthcare implementations, 200+ EHR integrations, zero HIPAA findings on shipped software. Our healthcare engineering team has been building inside healthcare environments — including DICOM, PACS, and specialty imaging systems — for over a decade. The depth shows up in the integration layer, where most generic imaging AI shops underdeliver.

Specialty imaging literacy. Our team has built imaging AI across radiology, pathology, ophthalmology, dermatology, and cardiology. We know what a PACS worklist looks like, what a DICOM-SR is for, what a digital pathology viewer’s API supports, and what a sonographer’s workflow needs from a quantification AI. Generic AI shops typically don’t have this.

FDA SaMD-awareness from project inception. Most generative AI shops haven’t engaged with FDA. Most generalist imaging AI shops engage with FDA at the end of the project. We engage from week one — scoping the validation methodology to support the regulatory pathway, structuring eval studies for regulatory-grade evidence, and partnering with regulatory consultants on the submission work.

The result: medical imaging AI we ship integrates with the PACS clinicians actually use, validates against clinician gold standards in studies that support regulatory submission where required, and continues running 18+ months after deployment without architectural drift.

Scope Your Medical Imaging AI Engagement

If you are building medical imaging AI for your healthtech product, your hospital, your health system, or a specific clinical specialty, book a 60-minute scoping call. We will walk through the use case, the modality, the data access reality, the PACS environment, the regulatory pathway requirements, and the validation expectations — and tell you whether the Imaging AI Prototype, Production Deployment, or FDA-Track Engagement is the right starting point, and what 12 weeks of engineering will produce.